|
Rethinking clinical trial endpoints in myelodysplastic syndromes.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Whole exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
|
Dec 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
|
May 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA As compared with BM
|
Aug 2017
|
Leukemia
|
aplastic anemia
|
|
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
|
Jul 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
|
Sep 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index
|
Sep 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Application of the International Prognostic Scoring System-Revised (IPSS-R) in Therapy-related Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia.
|
Jun 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
